TwitterRSSFacebookDirectors Blog
  Disorders A - Z:   A    B   C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z

You Are Here: Home  »  Research Funding  »  Offices & Programs  »  Neurodegeneration  » 

Skip secondary menu


The Neurodegeneration cluster portfolio consists of research on adult onset neurodegenerative diseases of all types, broadly focusing on pathogenesis, treatment and prevention. Research on the normal structure and function of neural systems is also included to enable identification of intervention strategies. The role of the programmatic team is to develop, implement and manage these research programs and to promote the translation of research findings into clinical practice.  Included in the portfolio are topics such as neuronal cell death, protein misfolding, aggregation, processing, mitochondrial pathologies, epidemiological studies, genetic studies, biomarker studies, clinical studies, including deep brain stimulation and gene therapy, and translational projects that will accelerate bench-to-bedside therapies for neurodegenerative disorders.

Quick Links

Workshop Summary

Neurodegeneration Funding Initiatives and Requests for Information

  • Biomarkers for Lewy Body Dementias (U01) RFA-16-022. The purpose of this funding opportunity announcement (FOA) is to 1) expand the collection of clinical data and biological specimens in the NINDS Parkinson’s Disease Biomarkers Program (PDBP), a community research resource, to include data from patients with Lewy Body Dementias (including Dementia with Lewy Bodies and Parkinson's Disease with Dementia), and 2) to support hypothesis-driven clinical research to discover biomarkers that will improve the efficiency and outcome of Phase II clinical trials for the Lewy Body dementias and to provide an expansion of this existing research resource center for dissemination of information and access by the scientific community for further advancing research in this field. Applications may include both of these goals if justified. Letter of intent due: April 16, 2016; Application due: May 10, 2016. Contact: Debra Babcock, MD, PhD.
  • Biomarkers for Discovery in Parkinsonism (U01) PAR-16-112.  The purpose of this FOA is to support hypothesis-driven research to discover human biomarkers in Parkinson’s disease and other Parkinsonian syndromes, as a component of the NINDS Parkinson’s Disease Biomarkers Program (PDBP). This FOA encourages biomarkers discovery projects in 1) genetically causal Parkinson's disease, especially for particular sub-types of Parkinson's Disease (PD), including genetic cohorts, biologically defined cohorts of idiopathic PD, or ethnic subgroups of idiopathic PD; 2) The differentiation of synucleinopathies (such as PD and Multiple System Atrophy (MSA) from tauopathies (such as Progressive Supranuclear Palsy and Corticobasal degeneration); or 3) to improve diagnostic differentiation between idiopathic/subtypes of PD and these disorders, as well as from Essential tremor. In order to further advance research in this area, broad sharing of biospecimens and associated data is a critical feature of the PDBP generally and of this FOA specifically. A timeline including milestones, which will be used to evaluate the application not only in peer review but also in consideration of the awarded project for funding of non-competing award years, is required for all studies. Letter of intent due 30 days prior to application due date. Application Due: Sept 6, 2016; Sept 6, 2017; Sept 6, 2018. Contact: Katrina Gwinn, M.D
  • Request to Access Parkinson's Disease Related-Biospecimens (X01) PAR-14-340. Applications to this X01 have a rolling submission. Submissions between December 16, 2015- February 15, 2016 will have a review date by March 15, 2016.  February 16-April 15, 2016 will have a review date by May 16, 2016. Submissions between April 16-July 15, 2016 will have a review date by August 15, 2016. Contact: Katrina Gwinn, M.D., Marg Sutherland, Ph.D.
  • Parkinson's Disease Biomarker Program (PDBP) Discovery Projects (U01) PAR-NS-14-259. The purpose of this funding opportunity announcement (FOA) is to support up to three years of study for the discovery, assay optimization, and replication stages required for the development of biological biomarkers for Parkinson's disease (PD). Application receipt date(s): February 4, 2016, May 4, 2016, by 5:00 PM local time of applicant organization. Contact: Katrina Gwinn, M.D., Marg Sutherland, Ph.D.
  • Center without Walls for the Identification and Validation of Molecular Mechanisms Contributing to Tau Pathogenesis and Associated Neurodegeneration in Frontotemporal Degeneration (FTD) (U54) RFA-NS-16-023.  The purpose of this FOA is to support innovative interdisciplinary, multi-institute research that will lead to the identification and validation of molecular mechanisms relevant to human biology that contribute to tau toxicity associated with Frontotemporal Degeneration (FTD). It is anticipated that this research will also contribute to tool development that can be applied to target validation in FTD clinical trials. Applications must include an administrative core, a scientific governance structure, a minimum of three research projects with milestone plans, resource core(s) that support the basic research efforts of at least two proposed research projects, a data coordination core that will facilitate the distribution of data generated through the Center without Walls with the broad research community and a human biology validation core that will support the validation of mechanisms identified and resources developed under this FOA. Synergy must be evident among Center research projects and cores, such that successful completion of the aims could not be accomplished without the Center structure. This FOA is in response to the Alzheimer's Disease Related Dementias (ADRD) challenges outlined in the 2015 update to the National Plan to Address Alzheimer's Disease. This FOA does not support clinical trials or projects focused predominantly on translational research activities. Letter of intent due: April 10, 2016. Application due: May 10, 2016.Contact: Marg Sutherland, Ph.D.
  • Small Vessel Vascular Contributions to Cognitive Impairment and Dementia (VCID) Biomarkers Consortium (U24) RFA-NS-019; Development Projects (UH2/UH3) RFA-NS-16-020; Mechanistic Basis of Diffuse White Matter Disease in Vascular Contributions to Cognitive Impairment and Dementia (VCID)(R01)   
    • Watch the  WebEx meeting

    • The purpose of RFA-NS-16-019 is to establish the Coordinating Center for the new Small Vessel Vascular Contributions to Cognitive Impairment and Dementia (VCID) Biomarkers Consortium. This FOA together with its companion FOA ("Small Vessel VCID Biomarkers Development Projects"; RFA-NS-16-020) establish the Small Vessel VCID Biomarkers Consortium. The Coordinating Center will consist of: (i) an Administrative Core responsible for organizing, coordinating and administratively driving Consortium activities; and (ii) a Data Core that will coordinate, receive, collect, and share data, including de-identified clinical data, from Small Vessel VCID Biomarker Development projects (see RFA-NS-16-020). A Milestone Plan with timelines is required in all applications. The timeline and milestones will be used to evaluate applications not only in peer review but also in consideration of the awarded project for funding of non-competing award years. LOI due: April 10, 2016; Application due: May 10, 2016.  Contact: Rod Corriveau, Ph.D.
    • The purpose of RFA-NS-16-020 is to support research that evaluates and further develops candidate predictive, diagnostic, target engagement and progression candidate biomarkers of small vessel cerebrovascular disease in human vascular contributions to cognitive impairment and dementia (VCID) and vascular/Alzheimer's mixed dementias. Biomarkers development projects funded under this FOA, with support from the Coordinating Center (RFA-NS-16-019), will: study biomarkers as individual projects and concurrently establish the interactive consortium (UH2, years 1-2); and then work together as a consortium to perform collaborative cross-project multi-disciplinary studies to further evaluate and develop the most promising biomarker candidates (UH3, years 3-5) to the point of being ready for large scale multi-site clinical validation studies including towards FDA qualification of small vessel VCID biomarkers for phase II and phase III clinical trials (to be carried out under future separate funding). LOI due: April 10, 2016; Application due: May 10, 2016. This FOA is only for studies related to human biomarkers; animal or other disease model studies are not responsive to this FOA unless they directly inform like measures that are performed in parallel in humans; additionally, clinical trials are not responsive.Contact: Rod Corriveau, Ph.D.
    • The purpose of RFA-NS-16-021 is to support hypothesis-testing research to elucidate cellular and molecular mechanisms that underlie diffuse white matter disease of vascular origin including multifocal, small, and silent brain infarcts that may contribute to cognitive impairment and dementia.Contact: Rod Corriveau, Ph.D.
  • NINDS Translational Research Opportunities:


In the News


Neurodegeneration Program Staff

Scientific Staff Research Area
Roderick Corriveau, Ph.D.
Program Director
Point of contact: AD, VCID, VCI and Vascular dementias
Alzheimer’s disease and vascular contributions to cognitive impairment and dementia (VCID) including vascular dementias and vascular cognitive impairment (VCI). For Alzheimer’s disease research, studies focused on molecular mechanisms of disease pathophysiology with areas of emphasis including but not limited to: (1) APP, beta-amyloid, presenilins, tau, neurotrophins and synaptic proteins; (2) animal models; (3) neuroinflammation; (4) post-translational protein modifications; (5) protein trafficking and clearance.
Amelie Gubitz, Ph.D.
Program Director
Point of contact: ALS, SBMA (Kennedy's Disease), HSP
Basic, translational, and clinical research studies of amyotrophic lateral sclerosis (ALS), X-linked spinal and bulbar muscular atrophy (SBMA, Kennedy's Disease), and hereditary spastic paraplegia (HSP).
Daniel Miller, Ph.D.
Program Director
Point of contact: HD
Basic and translational studies of Huntington's disease (HD) as well as invertebrate neuromuscular junction research.
Beth-Anne Sieber, Ph.D.
Program Director
Point of contact: PD, parkinsonisms, dystonia
Parkinson’s disease (PD), including molecular biology, cell biology, neurochemistry, deep brain stimulation (DBS), gene therapy, motor and non-motor manifestations. Parkinsonian disorders including multiple system atrophy (MSA) and progressive supranuclear palsy (PSP), and dystonia.
Margaret Sutherland, Ph.D.
Program Director
Point of contact: FTD
Frontotemporal dementia (FTD), Parkinson’s disease (PD), genome-wide association (GWA) studies, genetics, biomarkers, stem cells, protein and mitochondrial dynamics, translational research, and clinical trials.
Christine R. Swanson-Fischer, Ph.D.
Health Program Specialist
Jordan Gladman, Ph.D.
Health Program Specialist


Neuroscience Center
6001 Executive Blvd.
Bethesda, Maryland 20892